Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMLWKZ7)

Drug Name
GO-203-2c Drug Info
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 2 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
Cross-matching ID
PubChem CID
134819826
TTD Drug ID
DMLWKZ7

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Mucin-1 (MUC1) TTBHFYQ MUC1_HUMAN Inhibitor [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Mucin-1 (MUC1) DTT MUC1 3.485 8.525 9.106 5.714
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Acute myeloid leukaemia
ICD Disease Classification 2A60
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Mucin-1 (MUC1) DTT MUC1 4.59E-01 -0.07 -0.41
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT02204085) A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of Genus Oncology.